Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Ferret models of alpha-1 antitrypsin deficiency develop lung and liver disease
Nan He, … , John F. Engelhardt, Bradley H. Rosen
Nan He, … , John F. Engelhardt, Bradley H. Rosen
Published February 1, 2022
Citation Information: JCI Insight. 2022;7(5):e143004. https://doi.org/10.1172/jci.insight.143004.
View: Text | PDF
Research Article Pulmonology

Ferret models of alpha-1 antitrypsin deficiency develop lung and liver disease

  • Text
  • PDF
Abstract

Alpha-1 antitrypsin deficiency (AATD) is the most common genetic cause and risk factor for chronic obstructive pulmonary disease, but the field lacks a large-animal model that allows for longitudinal assessment of pulmonary function. We hypothesized that ferrets would model human AATD-related lung and hepatic disease. AAT-knockout (AAT-KO) and PiZZ (E342K, the most common mutation in humans) ferrets were generated and compared with matched controls using custom-designed flexiVent modules to perform pulmonary function tests, quantitative computed tomography (QCT), bronchoalveolar lavage (BAL) proteomics, and alveolar morphometry. Complete loss of AAT (AAT-KO) led to increased pulmonary compliance and expiratory airflow limitation, consistent with obstructive lung disease. QCT and morphometry confirmed emphysema and airspace enlargement, respectively. Pathway analysis of BAL proteomics data revealed inflammatory lung disease and impaired cellular migration. The PiZ mutation resulted in altered AAT protein folding in the liver, hepatic injury, and reduced plasma concentrations of AAT, and PiZZ ferrets developed obstructive lung disease. In summary, AAT-KO and PiZZ ferrets model the progressive obstructive pulmonary disease seen in AAT-deficient patients and may serve as a platform for preclinical testing of therapeutics including gene therapy.

Authors

Nan He, Xiaoming Liu, Amber R. Vegter, T. Idil A. Evans, Jaimie S. Gray, Junfeng Guo, Shashanna R. Moll, Lydia J. Guo, Meihui Luo, Ningxia Ma, Xingshen Sun, Bo Liang, Ziying Yan, Zehua Feng, Lisi Qi, Arnav S. Joshi, Weam Shahin, Yaling Yi, Katherine N. Gibson-Corley, Eric A. Hoffman, Kai Wang, Christian Mueller, John F. Engelhardt, Bradley H. Rosen

×

Figure 1

Generation and validation of an AAT-KO ferret.

Options: View larger image (or click on image) Download as PowerPoint
Generation and validation of an AAT-KO ferret.
(A) Schematic for Cas9-me...
(A) Schematic for Cas9-mediated disruption of the SERPINA1 locus in ferret zygotes. (B) Sequences of founders screened for expression, with the insertion and deletion polymorphisms they harbored depicted. (C) Western blot of plasma AAT protein in 4 AAT-KO ferrets and matched WT controls. Ponceau S–stained loading control is shown below. All draws were obtained at approximately 2 months old. (D) Inhibitory capacity of NE in increasing volumes of plasma from AAT-KO and control ferrets (n = 9 pairs; P value by mixed effects model, P = 1.6 × 10–5). (E) Quantification of NE inhibitory capacity based on AUC for each genotype in D (n = 9 pairs; P value by Student’s t test, P = 2.9 × 10–7). (F) Quantification of SERPINA1 mRNA expression in liver, normalized to GAPDH (n = 5 pairs; P value by Student’s t test, P < 0.05). (G) Localization of SERPINA1 transcripts and AAT protein in liver sections from a representative matched pair. Nuclei are counterstained with DAPI (blue). Scale bars: 50 μm. All graphs show mean ± SEM; some error bars are hidden by symbols. *P < 0.05; ****P < 0.0001.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts